GreenLight Biosciences up on approval for COVID vaccine trial in Rwanda

Greenlight Biosciences Holdings PBC

01/02/2023 13:11

** Shares of GreenLight Biosciences  GRNA.O  rise 4.6% to
$1.14 premarket
    ** Biotech co says it has received approval from Rwanda Food
and Drugs Authority to start an early-to-mid-stage trial for its
experimental COVID-19 mRNA vaccine 
    ** GreenLight along with partners is also developing mRNA
vaccines against other diseases such as shingles and cancer
    ** GRNA shares have lost ~45% over the past three months 
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))